Limits...
Prognostic role of platelet – lymphocyte ratio in colorectal cancer

View Article: PubMed Central - PubMed

ABSTRACT

Many studies have been reported that platelet–lymphocyte ratio (PLR) may be associated with the prognosis of colorectal cancer (CRC), but the results are inconsistent. Current opinion on the prognostic role of the PLR in CRC is inconsistent and inconclusive. Therefore, we conduct a meta-analysis that combines these studies and to identify the prognostic value of PLR in patients with CRC. Data were retrieved from PubMed, EMBASE, Cochrane Library, and Web of Science databases that came from inception through January 2016. We extracted data from the characteristics of each study and analyzed the relationship between PLR and overall survival (OS), disease-free survival (DFS), or other prognosis in patients with CRC by using the hazard ratio (HR) and 95% confidence intervals (95% CIs). Of the 256 identified studies, 15 studies were included and a total of 3991 patients were included. In a meta-analysis, patients with an elevated PLR had a significantly lower OS (pooled HR, 1.53; 95% CI, 1.24–1.89; P ≤ 0.001), DFS (pooled HR, 1.68; 95% CI, 1.07–2.62; P = 0.023). Even after sensitivity analyses and trim and fill method, high PLR remains significantly predictive poorer OS, but not DFS. In addition, our meta-analysis indicated that increased PLR is also significantly associated with the poor tumor differentiation [odds ratio (OR) 2.12; 95% CI, 1.45–3.08, P < 0.001)], the propensity toward depth of infiltration (OR 1.69; 95% CI, 1.20–2.39, P = 0.003), and recurrence in patients with CRC (HR, 2.71; 95% CI, 1.31–5.60, P = 0.005). This meta-analysis suggested that a high peripheral blood PLR can be used as a predictor of OS connected with clinicopathological parameters in patients with CRC, not DFS. These ratios may thus contribute to inform more personalized treatment decisions and predict treatment outcomes.

No MeSH data available.


Flow chat of literature search and selection.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4998446&req=5

Figure 1: Flow chat of literature search and selection.

Mentions: As shown in Fig. 1, we found that the initial search algorithm retrieved a total of 256 studies. After excluding 233 irrelevant or duplicate articles by screening the title and title and abstract, the left 23 full-text articles were reviewed. Of them, another 8 studies had to be excluded, as they were conference abstracts (n = 3), reports without associating PLR with survival parameters, such as OS or DFS (n = 2), or articles without sufficient data (n = 3). Finally, our meta-analysis included 15 studies with a total number of 3991 patients to assess the value of PLR as prognostic biomarkers in CRC. The basic characteristics of the 15 studies are summarized in Table 1. There were 14 studies that reported the association between the PLR and OS. Six studies evaluated the NLR for outcomes of patients. Of the 15 eligible articles, 4 studies were from China, 2 cohorts from the UK, 1 cohort from the Austria, 3 from the Korea, 3 from the Japan, 1 from Hungary, and 1 from Canada. Six groups in the original multivariate analysis directly provided HR, and there were 4 HRs coming from univariate analysis and 5 HRs deduced from survival curves. For the risk of OS, PLR was related with poor survival in 7 studies,[17–24] and the rest of studies did not show the relationship between the PLA and decreased survival.[15,25–30]


Prognostic role of platelet – lymphocyte ratio in colorectal cancer
Flow chat of literature search and selection.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4998446&req=5

Figure 1: Flow chat of literature search and selection.
Mentions: As shown in Fig. 1, we found that the initial search algorithm retrieved a total of 256 studies. After excluding 233 irrelevant or duplicate articles by screening the title and title and abstract, the left 23 full-text articles were reviewed. Of them, another 8 studies had to be excluded, as they were conference abstracts (n = 3), reports without associating PLR with survival parameters, such as OS or DFS (n = 2), or articles without sufficient data (n = 3). Finally, our meta-analysis included 15 studies with a total number of 3991 patients to assess the value of PLR as prognostic biomarkers in CRC. The basic characteristics of the 15 studies are summarized in Table 1. There were 14 studies that reported the association between the PLR and OS. Six studies evaluated the NLR for outcomes of patients. Of the 15 eligible articles, 4 studies were from China, 2 cohorts from the UK, 1 cohort from the Austria, 3 from the Korea, 3 from the Japan, 1 from Hungary, and 1 from Canada. Six groups in the original multivariate analysis directly provided HR, and there were 4 HRs coming from univariate analysis and 5 HRs deduced from survival curves. For the risk of OS, PLR was related with poor survival in 7 studies,[17–24] and the rest of studies did not show the relationship between the PLA and decreased survival.[15,25–30]

View Article: PubMed Central - PubMed

ABSTRACT

Many studies have been reported that platelet–lymphocyte ratio (PLR) may be associated with the prognosis of colorectal cancer (CRC), but the results are inconsistent. Current opinion on the prognostic role of the PLR in CRC is inconsistent and inconclusive. Therefore, we conduct a meta-analysis that combines these studies and to identify the prognostic value of PLR in patients with CRC. Data were retrieved from PubMed, EMBASE, Cochrane Library, and Web of Science databases that came from inception through January 2016. We extracted data from the characteristics of each study and analyzed the relationship between PLR and overall survival (OS), disease-free survival (DFS), or other prognosis in patients with CRC by using the hazard ratio (HR) and 95% confidence intervals (95% CIs). Of the 256 identified studies, 15 studies were included and a total of 3991 patients were included. In a meta-analysis, patients with an elevated PLR had a significantly lower OS (pooled HR, 1.53; 95% CI, 1.24–1.89; P ≤ 0.001), DFS (pooled HR, 1.68; 95% CI, 1.07–2.62; P = 0.023). Even after sensitivity analyses and trim and fill method, high PLR remains significantly predictive poorer OS, but not DFS. In addition, our meta-analysis indicated that increased PLR is also significantly associated with the poor tumor differentiation [odds ratio (OR) 2.12; 95% CI, 1.45–3.08, P < 0.001)], the propensity toward depth of infiltration (OR 1.69; 95% CI, 1.20–2.39, P = 0.003), and recurrence in patients with CRC (HR, 2.71; 95% CI, 1.31–5.60, P = 0.005). This meta-analysis suggested that a high peripheral blood PLR can be used as a predictor of OS connected with clinicopathological parameters in patients with CRC, not DFS. These ratios may thus contribute to inform more personalized treatment decisions and predict treatment outcomes.

No MeSH data available.